NCT00814489View on ClinicalTrials.gov

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 8, 2009

Primary Completion Date

May 4, 2009

Study Completion Date

June 10, 2010

Conditions
Streptococcus PneumoniaeHaemophilus Influenzae
Interventions
BIOLOGICAL

GSK2231395A

Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.

BIOLOGICAL

Engerix-B

Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.

Trial Locations (1)

SE-371 41

GSK Investigational Site, Karlskrona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY